II. Epidemiology
- Most common Leukemia in the United States
- Older patients
- Usually over age 50 years
- Age over 65 years old in 85% of new cases
- More common in men
- Rare in Asian patients
III. Pathophysiology
- Neoplastic accumulation of mature Lymphocytes
- Involves Blood and Bone Marrow
- May infiltrate Spleen and Lymph Nodes
- Clonal B Lymphocyte mass involved in 95% of cases
- Chromosomal Abnormality: Trisomy 12
IV. Symptoms
V. Signs
VI. Labs
-
Peripheral Smear
- Leukocytosis
- Morphologically normal small Leukocytes
-
Complete Blood Count
-
Leukocyte count 15,000 to 200,000 (80-90% mature)
- Clonal expansion of >5000 B Lymphocytes/mm3
- Decreased Platelet Count
- Hemoglobin or Hematocrit consistent with Anemia
-
Leukocyte count 15,000 to 200,000 (80-90% mature)
VII. Differential Diagnosis
- B-Cell CLL
- Reactive Lymphocytosis
-
T-Cell CLL
- Sezary Syndrome
- Adult T-Cell Leukemia
-
General
- Prolymphocytic Leukemia
- Lymphosarcoma Cell Leukemia
- Hairy Cell Leukemia
- Waldenstrom's Macroglobulinemia
VIII. Complications
- Pancytopenia
- Coombs-positive Hemolytic Anemia (20%)
- Hypogammaglobulinemia
- Opportunistic infection
- Richter's Syndrome (evolves into aggressive Lymphoma)
- Autoimmune Thrombocytopenia
IX. Imaging
-
Chest XRay
- Enlarged mediastinal Lymph Nodes
X. Management: Treatment
- Efficacy of treatment
- No regimen effective at eradicating CLL
- Goal is to reduce Leukemia cell mass and symptoms
-
Alkylating Agents (pulsed q3-6 weeks or continuous)
- Indications
- Hemolytic Anemia and other cytopenia
- Disfiguring Lymphadenopathy
- Symptomatic organomegaly
- Marked systemic symptoms
- Agents
- Chlorambucil
- Cyclophosphamide
- Indications
-
Glucocorticoids
- Coombs-positive Hemolytic Anemia
- Immune Thrombocytopenia
- Pancytopenia
- "Packed Marrow" Syndrome
- Splenectomy indications
- Hypersplenism
- Refractory Hemolytic Anemia
- Thrombocytopenia
-
Radiation Therapy indications
- Localized disease
- Palliative end-stage disease therapy (total-body)
- Immunoglobulin transfusion (not proven efficacious)
XI. Management: Surveillance for those under observation only (no treatment)
- Periodic constitutional symptom history
- Fatigue
- Weight loss
- Night Sweats
- Fever
- Periodic exam
- Periodic Complete Blood Count (CBC)
- Hematology Consultation for Anemia or Thrombocytopenia
-
Vaccination
- Influenza Vaccine yearly
- Pneumococcal Vaccine yearly
- Avoid Live Vaccines
- Routine cancer screening (appropriate for age and gender)
XII. Management: Surveillance for those who have been treated
- Cardiology Consultation for baseline examination
- Periodic Echocardiogram (rest and stress)
- Frequency depends on risks and Echocardiogram findings
XIII. Course
- Indolent nature
- Often incidental finding on Complete Blood Count
XIV. Staging
- Stage A: Lymphocytosis (<3 Lymph Node groups involved)
- Median survival: over 10 years
- Stage B: Lymphocytosis (>3 Lymph Node groups involved)
- Median survival: 5 years
- Stage C: Lymphocytosis with Anemia or Thrombocytopenia
- Median survival: 2 years
XV. Prognosis
- Age <50 years old: 94% five-year survival
- Age >50 years old: 83% five-year survival